Display options
Cite
Wiklund I, Berg G, Hammar M, et al. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas. 1992;14(3):225-36doi: 10.1016/0378-5122(92)90117-m.
Wiklund, I., Berg, G., Hammar, M., Karlberg, J., Lindgren, R., & Sandin, K. (1992). Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas, 14(3), 225-36. https://doi.org/10.1016/0378-5122(92)90117-m
Wiklund, I, et al. "Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women." Maturitas vol. 14,3 (1992): 225-36. doi: https://doi.org/10.1016/0378-5122(92)90117-m
Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R, Sandin K. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas. 1992 Mar;14(3):225-36. doi: 10.1016/0378-5122(92)90117-m. PMID: 1508062.
Copy Download .nbib Format: NLM
Share it on
Full text links
Elsevier Science

Maturitas. 1992 Mar;14(3):225-36. doi: 10.1016/0378-5122(92)90117-m.

Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women.

Maturitas

I Wiklund, G Berg, M Hammar, J Karlberg, R Lindgren, K Sandin

Affiliations

  1. Department of Medicine, Ostra Hospital, Göteborg, Sweden.

PMID: 1508062 DOI: 10.1016/0378-5122(92)90117-m

Abstract

The long-term effect on aspects of quality of life (QoL) of treatment with transdermal oestrogen for 2 weeks followed by transdermal oestrogen/progestogen norethisterone acetate/oestradiol TTS 0.25/0.05 mg/day for the next 2 weeks was investigated in postmenopausal women within the framework of a 1-year seven-centre trial. Of the 136 women who were included (mean age 53 +/- 4.8 years), 110 completed the study. Aspects of QoL that are of relevance in the perimenopause and postmenopause were evaluated using the Psychological General Well-Being (PGWB) index, the Women's Health Questionnaire (WHQ) and the Sleep Dysfunction Scale before and after 3 and 9 months of therapy in the oestrogen phase. Climacteric complaints were also assessed by means of the Kupperman Index. Improved well-being, i.e. less anxiety and depression, increased vitality and better self-control (P less than 0.0001) were observed, as well as reduced sleep disturbance (P less than 0.0001). The WHQ showed decreased vasomotor and somatic symptoms, and improved sex life, emotions and cognitive function (P less than 0.0001). Improvement was the same at 3 and 9 months. According to the Kupperman Index, climacteric symptoms were alleviated (P less than 0.0001). Relief of vasomotor symptoms was correlated with improvement in the WHQ (r = 0.82), the PGWB index (r = 0.58, P less than 0.0001) and sleep (r = 0.51, P less than 0.0001). Because of the absence of a placebo control group, the results must be regarded with caution until confirmed in a placebo-controlled trial.

Similar articles

Substances

MeSH terms

Publication Types

LinkOut - more resources